A downtrend has been apparent in Artivion (AORT) lately with too much selling pressure. The stock has declined 18.6% over the ...

Medical device company Artivion (NYSE:AORT) in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s ...

Artivion Price Performance Shares of NYSE AORT opened at $25.34 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a fifty ...

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 results. The ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-reports-fourth-quarter-and-full-year-2024-financial-results-302383788 ...

Artivion (AORT) delivered earnings and revenue surprises of -100% and 3.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Artivion shares have dropped nearly 3% since the beginning of the year. In the final minutes of trading on Monday, shares hit $27.85, an increase of 41% in the last 12 months.

Medical device company Artivion (NYSE:AORT) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 3.9% year on year to $97.31 million. The company’s full-year revenue guidance ...

Booking Holdings and Mizuho Financial are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...